Grifols (GRFS) Net Shares Issued and Repurchased (2010 - 2016)
Grifols' (GRFS) quarterly Net Shares Issued and Repurchased came in at $12.7 million in Q4 2016, up 191.3% YoY from $4.4 million in Q1 2016, and up 271.37% on a QoQ basis from -$7.4 million in Q3 2016.
Grifols (GRFS) Net Shares Issued and Repurchased (2010 - 2016) Analysis & Trends
Grifols (GRFS) has 7 years of Net Shares Issued and Repurchased data on file, last reported at $12.7 million in Q4 2016.
- Quarterly Net Shares Issued and Repurchased rose 191.3% year-over-year to $12.7 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$8.6 million (up 53.87% YoY) and the FY2021 annual result came in at -$143.8 million, changed N/A from the prior year.
- Net Shares Issued and Repurchased grew to $12.7 million in Q4 2016, from -$7.4 million in the prior quarter.
- In the past five years, Net Shares Issued and Repurchased ranged from a high of $220.2 million in Q2 2013 to a low of -$110.0 million in Q1 2013.
- A 5-year average of $2.6 million and a median of -$60856.2 in 2014 frame the typical range for Net Shares Issued and Repurchased.
- Annual changes were most pronounced in 2013 — Net Shares Issued and Repurchased slumped 4193096.4% — and 2014, when it jumped 212.22%.
- Tracing GRFS's Net Shares Issued and Repurchased over 5 years: stood at -$14265.8 in 2012, then plunged by 478157.35% to -$68.2 million in 2013, then jumped by 212.22% to $76.6 million in 2014, then plunged by 118.16% to -$13.9 million in 2015, then surged by 191.3% to $12.7 million in 2016.
- The last three Net Shares Issued and Repurchased figures came in at $12.7 million (Q4 2016), -$7.4 million (Q3 2016), and -$13.9 million (Q4 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 12.69 Mn |
| Dec 31, 2016 | 12.69 Mn |
| Sep 30, 2016 | -7.41 Mn |
| Sep 30, 2016 | -7.41 Mn |
| Dec 31, 2015 | -13.90 Mn |
| Dec 31, 2015 | -13.90 Mn |
| Dec 31, 2014 | 76.56 Mn |
| Dec 31, 2014 | 76.56 Mn |
| Sep 30, 2014 | -81.34 Mn |
| Sep 30, 2014 | -81.34 Mn |
| Jun 30, 2014 | -60,856.23 |
| Jun 30, 2014 | -60,856.23 |
| Dec 31, 2013 | -68.23 Mn |
| Dec 31, 2013 | -68.23 Mn |
| Jun 30, 2013 | 220.19 Mn |
| Jun 30, 2013 | 220.19 Mn |
| Mar 31, 2013 | -109.97 Mn |
| Mar 31, 2013 | -109.97 Mn |
| Dec 31, 2012 | -14,265.82 |
| Dec 31, 2012 | -14,265.82 |